Compugen traded at 665.10 this Wednesday March 25th, increasing 18.60 or 2.88 percent since the previous trading session. Looking back, over the last four weeks, Compugen gained 20.23 percent. Over the last 12 months, its price rose by 19.15 percent. Looking ahead, we forecast Compugen to be priced at 645.68 by the end of this quarter and at 590.75 in one year, according to Trading Economics global macro models projections and analysts expectations.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.